Skip to content

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity | Weight Gain

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    12 to 17

Participation Criteria

Inclusion Criteria:

* Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
* Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
* Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).

Exclusion Criteria:

* Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to

* gastric bypass
* sleeve gastrectomy
* restrictive bariatric surgery, such as Lap-Band gastric banding, or
* any other procedure intended to result in weight reduction.
* Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
* Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state
* Have type 2 diabetes or have a HbA1c \> 6.4% at screening
* Have a history of chronic or acute pancreatitis
* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Study Location

Alberta Children's Hospital
Alberta Children's Hospital
Calgary, Alberta
Canada

Contact Study Team

Bluewater Clinical Research Group Inc.
Bluewater Clinical Research Group Inc.
Sarnia, Ontario
Canada

Contact Study Team

Premier Clinical Trial Network
Premier Clinical Trial Network
Hamilton, Ontario
Canada

Contact Study Team

Kids Clinic
Kids Clinic
Ajax, Ontario
Canada

Contact Study Team

Maison de Santé Prévention
Maison de Santé Prévention
Montreal, Quebec
Canada

Contact Study Team

Dr. Steven V. Zizzo Research Professional Corporation
Dr. Steven V. Zizzo Research Professional Corporation
Hamilton, Ontario
Canada

Contact Study Team

Winterberry Research Inc.
Winterberry Research Inc.
Hamilton, Ontario
Canada

Contact Study Team

Study Sponsored By
Eli Lilly and Company
Participants Required
More Information
Study ID: NCT06439277